We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Morphic
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 25, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (PFE - Free Report) , BioNTech (BNTX - Free Report) , Moderna (MRNA - Free Report) and Morphic (MORF - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Pfizer, BioNTech Post Data on Covid Jab for Kids Under 5
Pfizer and partner BioNTech announced newly-updated data from a phase II/III study, evaluating the three-dose primary regimen of the Pfizer-BioNTech COVID-19 Vaccine in children aged six months through four years of age.
An updated analysis of phase II/III study showed that the vaccine efficacy was 73.2% in this age group diagnosed between March 2022 and June 2022, during which COVID-19 infections were due to the Omicron BA.2 subvariant.
The phase II/III study divided the study participants into two groups — one aged between six months through 23 months and another aged two years through four years. In the first group, the study achieved a vaccine efficacy of 75.8%, while vaccine efficacy was 71.8% in the second group.
A 3-µg dose of this vaccine was granted emergency use authorization (EUA) by the FDA for use in children aged six months through four years, earlier this year in June based on preliminary data based on 10 symptomatic COVID-19 cases from the same study.
However, a similar application seeking expanded authorization for using their COVID-19 vaccine in children aged six months through four years is under review in the European Union. The vaccine is already authorized for use in individuals aged five years and older at different dose levels in several countries, including the United States and EU.
Pfizer and BioNTech plan to share the above-mentioned data with regulatory authorities across the world, including the United States and Europe, in the coming weeks. Pfizer/BioNTech are preparing a EUA application for an Omicron BA.4/BA.5-adapted bivalent vaccine in children six months through 11 years of age.
Shares of Pfizer have lost 18.7% in the year so far against the industry’s 0.4% rise.
Shares of BioNTech have plunged 42.9% in the year compared with the industry’s 22.3% fall.
The COVID-19 vaccines developed by Pfizer and BioNTech are based on mRNA technology. Another vaccine based on mRNA technology, which poses stiff competition to the Pfizer/BioNTech vaccine, has been developed by Moderna.
Like Pfizer/BioNTech’s vaccine, Moderna’s vaccine is also authorized for use in all individuals aged six months and older at varying dose levels.
The Pfizer/BioNTech and Moderna vaccines combined to dominate the U.S. market. In fact, they are the only jabs that have received full approval for use in the country. While Moderna’s vaccine is approved for use in adults aged 18 years and older, the Pfizer/BioNTech vaccine is approved for use in individuals aged 12 years and older. A third and fourth booster dose of Moderna and Pfizer/BioNTech vaccines have also been authorized for use in certain age groups by the FDA.
Earlier this week, Moderna and Pfizer/BioNTech announced that they completed their respective regulatory filings with the FDA seeking approval for their bivalent BA.4/BA.5 Omicron-targeting COVID-19 vaccine. While Pfizer and BioNTech seek authorization in individuals aged 12 years and older, Moderna seeks authorization in adults aged 18 years and older.
These bivalent vaccines have been developed considering the FDA’s recommendation to target the BA.4 and BA.5 subvariants. Pfizer/BioNTech and Moderna have also scaled production of these bivalent vaccines and will be ready to ship doses as soon as the FDA grants its authorization.
Pfizer and BioNTech currently carry a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Morphic, which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, estimates for Morphic’s 2022 loss per share have narrowed from $3.38 to $1.75. Loss estimates for 2023 have narrowed from $3.91 to $3.77 during the same period. Shares of Morphic have lost 35.1% in the year-to-date period.
Earnings of Morphic beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 48.29%, on average. In the last reported quarter, MORF delivered an earnings surprise of 183.95%.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Morphic
For Immediate Release
Chicago, IL – August 25, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (PFE - Free Report) , BioNTech (BNTX - Free Report) , Moderna (MRNA - Free Report) and Morphic (MORF - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Pfizer, BioNTech Post Data on Covid Jab for Kids Under 5
Pfizer and partner BioNTech announced newly-updated data from a phase II/III study, evaluating the three-dose primary regimen of the Pfizer-BioNTech COVID-19 Vaccine in children aged six months through four years of age.
An updated analysis of phase II/III study showed that the vaccine efficacy was 73.2% in this age group diagnosed between March 2022 and June 2022, during which COVID-19 infections were due to the Omicron BA.2 subvariant.
The phase II/III study divided the study participants into two groups — one aged between six months through 23 months and another aged two years through four years. In the first group, the study achieved a vaccine efficacy of 75.8%, while vaccine efficacy was 71.8% in the second group.
A 3-µg dose of this vaccine was granted emergency use authorization (EUA) by the FDA for use in children aged six months through four years, earlier this year in June based on preliminary data based on 10 symptomatic COVID-19 cases from the same study.
However, a similar application seeking expanded authorization for using their COVID-19 vaccine in children aged six months through four years is under review in the European Union. The vaccine is already authorized for use in individuals aged five years and older at different dose levels in several countries, including the United States and EU.
Pfizer and BioNTech plan to share the above-mentioned data with regulatory authorities across the world, including the United States and Europe, in the coming weeks. Pfizer/BioNTech are preparing a EUA application for an Omicron BA.4/BA.5-adapted bivalent vaccine in children six months through 11 years of age.
Shares of Pfizer have lost 18.7% in the year so far against the industry’s 0.4% rise.
Shares of BioNTech have plunged 42.9% in the year compared with the industry’s 22.3% fall.
The COVID-19 vaccines developed by Pfizer and BioNTech are based on mRNA technology. Another vaccine based on mRNA technology, which poses stiff competition to the Pfizer/BioNTech vaccine, has been developed by Moderna.
Like Pfizer/BioNTech’s vaccine, Moderna’s vaccine is also authorized for use in all individuals aged six months and older at varying dose levels.
The Pfizer/BioNTech and Moderna vaccines combined to dominate the U.S. market. In fact, they are the only jabs that have received full approval for use in the country. While Moderna’s vaccine is approved for use in adults aged 18 years and older, the Pfizer/BioNTech vaccine is approved for use in individuals aged 12 years and older. A third and fourth booster dose of Moderna and Pfizer/BioNTech vaccines have also been authorized for use in certain age groups by the FDA.
Earlier this week, Moderna and Pfizer/BioNTech announced that they completed their respective regulatory filings with the FDA seeking approval for their bivalent BA.4/BA.5 Omicron-targeting COVID-19 vaccine. While Pfizer and BioNTech seek authorization in individuals aged 12 years and older, Moderna seeks authorization in adults aged 18 years and older.
These bivalent vaccines have been developed considering the FDA’s recommendation to target the BA.4 and BA.5 subvariants. Pfizer/BioNTech and Moderna have also scaled production of these bivalent vaccines and will be ready to ship doses as soon as the FDA grants its authorization.
Pfizer Inc. price | Pfizer Inc. Quote
BioNTech SE Sponsored ADR price | BioNTech SE Sponsored ADR Quote
Zacks Rank & Stock to Consider
Pfizer and BioNTech currently carry a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Morphic, which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, estimates for Morphic’s 2022 loss per share have narrowed from $3.38 to $1.75. Loss estimates for 2023 have narrowed from $3.91 to $3.77 during the same period. Shares of Morphic have lost 35.1% in the year-to-date period.
Earnings of Morphic beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 48.29%, on average. In the last reported quarter, MORF delivered an earnings surprise of 183.95%.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.